Children's Tumor Foundation

Christina Cucolo studies cell-free DNA as a potential biomarker for NF1 in Dr. Taylor Sundby’s lab at Nemours. Her connection to NF is also personal: her cousin Brian lives with NF2-related schwannomatosis. This year, Christina is bringing her research, personal connection, and love of running together as a member of CTF’s NF Endurance team for the New...

Two approved treatments for plexiform neurofibromas, the first-ever NF1 platform trial launching in Europe, and 50 active CTF-funded research investigations across the pipeline: that was the picture of NF1 research shared at the Children’s Tumor Foundation’s (CTF) recent webinar, “What’s Next for NF1: Progress in the Research Pipeline, Clinical Trials and ...

On November 16, 2026, the Children’s Tumor Foundation will honor Gabe Groisman, Chair of the CTF Board of Directors, with the Humanitarian Award at the National Gala in New York City.

The award recognizes Gabe’s extraordinary leade...

Growing up brings new experiences, responsibilities, and questions. For teens living with neurofibromatosis type 1 (NF1), those questions may include understanding changes in their health, navigating friendships, advocating for themselves, and preparing for adulthood.

These topics were the focus of a recent Children’s Tumor Foundation (CTF) NF Knowl...

A continuing medical education (CME) activity for healthcare professionals caring for pediatric and adult patients with neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN).

Managing NF1-PN requires a coordinated approach across a patient’s lifetime. Timely diagnosis, appropriate treatment selection, and continuity of care...